Scholarlink

Background <p>Efforts to predict the outcomes of patients with gastric cancer (GC) following immune checkpoint inhibitor (ICI) treatments remain limited, owing to a lack of reliable biomarkers. Studies have found that extracellular vesicle (EV)-derived lncRNA-GC1 may serve as a GC-specific biomarker. This study was designed to expand on these previous results by estimating the usefulness of EV-derived lncRNA-GC1 as a predictive indicator for patients with GC who undergo ICI treatments.</p> Methods <p>EV-derived lncRNA-GC1 levels were measured using real-time polymerase chain reaction (RT-PCR) in patients with unresectable or metastatic GC who were receiving ICI treatments. Correlations between this biomarker and ICI treatment outcomes were analyzed in a training cohort (<i>n</i> = 136), two external validation cohorts (<i>n</i> = 188 and <i>n</i> = 214), one expanding cohort (<i>n</i> = 30), and one prospective cohort (<i>n</i> = 192).</p> Results <p>Circulating EVs exhibited a lncRNA-GC1 expression profile that was distinct from that of tissues or circulating cells. EV-derived lncRNA-GC1 levels were found to be independent of PD-L1 expression status or the density of CD8<sup>+</sup> T cell infiltration. EV-derived lncRNA-GC1 could be used to effectively predict ICI-related patient outcomes, and could be used for dynamic monitoring throughout treatments. Lower levels of EV-derived lncRNA-GC1 were associated with tumor microenvironmental characteristics such as more robust antitumor immunity—including higher levels of activated CD8<sup>+</sup> T/NK cells and an increased TH1/TH2 ratio. Such biomarkers can be stably detected in clinical practice. These results were consistent in both the two external validation cohorts and the one prospective cohort.</p> Conclusions <p>EV-derived lncRNA-GC1 can be used to reliably predict immunotherapeutic outcomes in patients with GC who undergo ICI treatments, suggesting that targeted analyses of this lncRNA may be useful for guiding treatment planning, monitoring, and associated decision-making processes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月27日

查看全文
  • Jiangpeng Wei,
  • Xinxin Wang,
  • Danhong Dong,
  • Yi Ru,
  • Lubin Chen,
  • Xin Cheng,
  • Xiaohui Lv,
  • Xin Guo

摘要

Background

Efforts to predict the outcomes of patients with gastric cancer (GC) following immune checkpoint inhibitor (ICI) treatments remain limited, owing to a lack of reliable biomarkers. Studies have found that extracellular vesicle (EV)-derived lncRNA-GC1 may serve as a GC-specific biomarker. This study was designed to expand on these previous results by estimating the usefulness of EV-derived lncRNA-GC1 as a predictive indicator for patients with GC who undergo ICI treatments.

Methods

EV-derived lncRNA-GC1 levels were measured using real-time polymerase chain reaction (RT-PCR) in patients with unresectable or metastatic GC who were receiving ICI treatments. Correlations between this biomarker and ICI treatment outcomes were analyzed in a training cohort (n = 136), two external validation cohorts (n = 188 and n = 214), one expanding cohort (n = 30), and one prospective cohort (n = 192).

Results

Circulating EVs exhibited a lncRNA-GC1 expression profile that was distinct from that of tissues or circulating cells. EV-derived lncRNA-GC1 levels were found to be independent of PD-L1 expression status or the density of CD8+ T cell infiltration. EV-derived lncRNA-GC1 could be used to effectively predict ICI-related patient outcomes, and could be used for dynamic monitoring throughout treatments. Lower levels of EV-derived lncRNA-GC1 were associated with tumor microenvironmental characteristics such as more robust antitumor immunity—including higher levels of activated CD8+ T/NK cells and an increased TH1/TH2 ratio. Such biomarkers can be stably detected in clinical practice. These results were consistent in both the two external validation cohorts and the one prospective cohort.

Conclusions

EV-derived lncRNA-GC1 can be used to reliably predict immunotherapeutic outcomes in patients with GC who undergo ICI treatments, suggesting that targeted analyses of this lncRNA may be useful for guiding treatment planning, monitoring, and associated decision-making processes.